Biologic Drugs With Established Pharmaceutical Class: CD20-directed Cytolytic Antibody

✉ Email this page to a colleague

Biologic Drugs With Established Pharmaceutical Class: CD20-directed Cytolytic Antibody

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	1997-11-26	⤷ Sign Up	⤷ Sign Up
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	2009-10-26	⤷ Sign Up	⤷ Sign Up
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	2013-11-01	⤷ Sign Up	⤷ Sign Up
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	2017-03-28	⤷ Sign Up	⤷ Sign Up
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	2017-06-22	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.